Michael I. Walton

3.4k citations

49 papers · 2.5k indexed · h-index 28

Impact in

Toxicology top 0.5%
- Bioactive Compounds and Antitumor Agents
Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism

Papers in

Pharmacology 9
- Pharmacogenetics and Drug Metabolism 9
Toxicology 3
- Bioactive Compounds and Antitumor Agents 3

Co-authors: Paul Workman Florence I. Raynaud Lloyd R. Kèlland C. Roland Wolf Ian Judson Udai Banerji S J Korsmeyer Kurt W. Kohn
Journals: Biochemical Pharmacology (7 papers)International Journal of Radiation Oncology*Biology*Physics (6 papers)Cancer Chemotherapy and Pharmacology (4 papers)Cancer Research (3 papers)Molecular Cancer Therapeutics (2 papers)
Partner nations: United Kingdom United States Portugal

In The Last Decade

Michael I. Walton

49 papers receiving 2.4k citations

Peers

Countries citing papers authored by Michael I. Walton

Since Specialization

Citations

This map shows the geographic impact of Michael I. Walton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael I. Walton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael I. Walton more than expected).

Fields of papers citing papers by Michael I. Walton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael I. Walton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael I. Walton. The network helps show where Michael I. Walton may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael I. Walton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael I. Walton Line = papers co-authored together Michael I. Walton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells Cancer Research ·Rebecca F. Rogers, Michael I. Walton, Daniel L. Cherry, Ian Collins, Paul A. Clarke, Michelle D. Garrett, Paul Workman	2020	41
2	DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer Genome biology ·Nnennaya Kanu, Maria Antonietta Cerone, Gerald Goh, Lykourgos‐Panagiotis Zalmas, Jiřina Bártková, Michelle Dietzen, Nicholas McGranahan, Rebecca F. Rogers, Emily K. Law, Irina Gromova, Maik Kschischo, Michael I. Walton, Olivia W. Rossanese, Jiří Bártek, Reuben S. Harris, Subramanian Venkatesan, Charles Swanton	2016	118
3	CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors Cancer Research ·Victoria E. Anderson, Michael I. Walton, Paul D. Eve, K. Boxall, Laurent Antoni, John Caldwell, Wynne Aherne, Laurence H. Pearl, Antony W. Oliver, Ian Collins, Michelle D. Garrett	2011	79
4	The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 Molecular Cancer Therapeutics ·Michael I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis de Haven Brandon, Gary Box, Kathy Boxall, G. Wynne Aherne, Suzanne A. Eccles, Florence I. Raynaud, D. H. Williams, John Reader, Ian Collins, Michelle D. Garrett	2010	63
5	Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells Cancer Research ·Nathalie Gaspar, Swee Y. Sharp, Simon Pacey, Chris Jones, Michael I. Walton, Gilles Vassal, Suzanne A. Eccles, Andrew D.J. Pearson, Paul Workman	2009	92
6	Identification of Inhibitors of Checkpoint Kinase 1 through Template Screening Journal of Medicinal Chemistry ·Thomas P. Matthews, Suki Klair, Samantha Burns, Kathy Boxall, Michael Cherry, Martin Fisher, Isaac M. Westwood, Michael I. Walton, Tatiana McHardy, Kwai-Ming J. Cheung, Rob van Montfort, David J. Williams, G. Wynne Aherne, Michelle D. Garrett, John Reader, Ian Collins	2009	35
7	An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models Cancer Chemotherapy and Pharmacology ·Udai Banerji, Nivedita Sain, Swee Y. Sharp, Melanie Valenti, Yasmin J. Asad, Ruth Ruddle, Florence I. Raynaud, Michael I. Walton, Suzanne A. Eccles, Ian Judson, Ann L. Jackman, Paul Workman	2008	30
8	The Cyclin-Dependent Kinase Inhibitor Seliciclib (R-roscovitine; CYC202) Decreases the Expression of Mitotic Control Genes and Prevents Entry into Mitosis Cell Cycle ·Steven R. Whittaker, Robert te Poele, Florence Chan, Spiros Linardopoulos, Michael I. Walton, Michelle D. Garrett, Paul Workman	2007	54
9	Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models Clinical Cancer Research ·Udai Banerji, Michael I. Walton, Florence I. Raynaud, Rachel Grimshaw, Lloyd R. Kèlland, Melani Valenti, Ian Judson, Paul Workman	2005	126
10	Assays for HSP90 and Inhibitors Humana Press eBooks ·Wynne Aherne, Alison Maloney, Chrisostomos Prodromou, Martin Rowlands, Anthea Hardcastle, K. Boxall, Paul A. Clarke, Michael I. Walton, Laurence H. Pearl	2003	23
11	Effect of p53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line Molecular Pharmacology ·Katharine Pestell, Stephen M. Hobbs, Jenny Titley, Lloyd R. Kelland, Michael I. Walton	2000	5
12	Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120 Cancer Chemotherapy and Pharmacology ·Michael I. Walton, Phyllis M. Goddard, Lloyd R. Kèlland, David E. Thurston, Kenneth R. Harrap	1996	23
13	Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice. Journal of Pharmacology and Experimental Therapeutics ·Michael I. Walton, Paul Workman	1993	27
14	DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas European Journal of Cancer ·Michael I. Walton, Michael C. Bibby, John A. Double, Jane A. Plumb, Paul Workman	1992	48
15	Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinones International Journal of Radiation OncologyBiologyPhysics ·Samantha Bailey, N. Suggett, Michael I. Walton, Paul Workman	1992	37
16	The Role of NAD(P)H: Quinone Reductase (EC 1.6.99.2, DT-Diaphorase) in the Reductive Bioactivation of the Novel Indoloquinone Antitumor Agent E09 PubMed ·Michael I. Walton, Paul J. Smith, Paul Workman	1991	115
17	Enzymology of the reductive bioactivation of SR 4233 Biochemical Pharmacology ·Michael I. Walton, Paul Workman	1990	59
18	Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins International Journal of Radiation OncologyBiologyPhysics ·Michael I. Walton, C. Roland Wolf, Paul Workman	1989	63
19	A microcomputer controlled, local hyperthermia system for uniform tumour heating in unanaesthetized mice International Journal of Hyperthermia ·Michael I. Walton, D.M. Cattermole, N M Bleehen	1989	5
20	Interactions of Hyperthermia with Hypoxic Cell Sensitisers Recent results in cancer research ·N M Bleehen, Michael I. Walton, Paul Workman	1988	4

About Michael I. Walton

Michael I. Walton is a scholar working on Pharmacology, Toxicology, Cancer Research, Oncology and Molecular Biology, having authored 49 papers that have together received 2.5k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (13 papers), Cancer-related Molecular Pathways (12 papers), DNA Repair Mechanisms (9 papers), Pharmacogenetics and Drug Metabolism (9 papers), Cancer, Hypoxia, and Metabolism (8 papers), Heat shock proteins research (4 papers), Cancer Research and Treatments (3 papers) and Bioactive Compounds and Antitumor Agents (3 papers). The work is most often cited by research in Toxicology (248 citations), Cancer Research (442 citations), Oncology (719 citations), Molecular Biology (1.7k citations) and Pharmacology (146 citations). Michael I. Walton has collaborated with scholars based in United Kingdom, United States and Portugal. Frequent co-authors include Paul Workman, Florence I. Raynaud, Lloyd R. Kèlland, C. Roland Wolf, Ian Judson, Udai Banerji, S J Korsmeyer, Kurt W. Kohn, Patrick M. O’Connor and David M. Hockenbery. Their work appears in journals such as Biochemical Pharmacology, International Journal of Radiation Oncology*Biology*Physics, Cancer Chemotherapy and Pharmacology, Cancer Research and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact